Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

IK-930

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ikena Oncology

Drug class:

TEAD1 inhibitor

Related drugs:

‹

›

NF2 deletion	Malignant Pleural Mesothelioma	NF2 deletion	Malignant Pleural Mesothelioma	IK-930 Sensitive: B - Late Trials IK-930 Sensitive : B	IK-930 Sensitive: B - Late Trials IK-930 Sensitive : B
KRAS mutation	Mesothelioma	KRAS mutation	Mesothelioma	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D
EGFR mutation	Mesothelioma	EGFR mutation	Mesothelioma	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D
EGFR mutation	Colorectal Cancer	EGFR mutation	Colorectal Cancer	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D	IK-930 Sensitive: D – Preclinical IK-930 Sensitive : D